510(k) summary/statement reg
This article was originally published in The Gray Sheet
Executive Summary
FDA final rule, expected to issue this month, will revise an April 1992 interim rule to ensure that confidential or proprietary information is not released, according to agency staffers. The reg will spell out requirements for either submitting a summary of safety and effectiveness information with a 510(k) or submitting a statement that the information will be made available upon request. The reg also will cover requirements that Class III 510(k)s include summaries of and citations to safety and effectiveness information. In May 1992, the Health Industry Manufacturers Association successfully petitioned the agency to delay implementation of its interim rule, in part over concerns that the proposal would have required release of confidential information ("The Gray Sheet" June 1, 1992, p. 11)
You may also be interested in...
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.
Biden Administration Is Setting An Example For Safe AI Use In Federal Organizations
A new memorandum by the Director of the Office of Management and Budget initiated a government-wide policy that will appoint AI officers to all agencies to address risks for AI use and serve as an example for greater AI adoption.